Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

BPC-157 vs ARA-290

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

ARA-290 has stronger documented evidence (Phase 2) than BPC-157 (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. BPC-157 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

BPC-157

Anecdotal + Animal Studies

ARA-290

Phase 2

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

BPC-157 ARA-290
Class Synthetic pentadecapeptide; cytoprotective EPO-derived peptide; innate repair receptor (IRR) agonist
Drug class Tissue Repair Tissue Repair
Mechanism Promotes angiogenesis via VEGFR2 [1]; upregulates growth factors [1]; modulates NO and dopamine pathways [1]; stabilizes gut barrier [1] Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect
Route SC / IM / Oral / Intranasal SC injection
Half-life less than 30 min (IV and IM in rats and dogs; oral not measured) ~2 hrs
Dosage (research) 250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily 2-4 mg SC daily for 28 days (trial protocol)
Evidence tier Anecdotal + Animal Studies Phase 2
Research depth 190 indexed (PubMed 161 · CT 4 · EPMC 25) 68 indexed (PubMed 51 · CT 4 · EPMC 13)
Availability Compounding Restricted Investigational
Reported risks Limited human trials [1]; injection site irritation; theoretical pro-angiogenic/tumor concerns [1] Injection site reactions; Phase 2/3 data limited

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick BPC-157 or ARA-290?

ARA-290 has stronger documented evidence (Phase 2) than BPC-157 (Anecdotal + Animal Studies) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. BPC-157 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between BPC-157 and ARA-290?

BPC-157 is classed as Synthetic pentadecapeptide; cytoprotective; ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist. Reported mechanism: BPC-157, Promotes angiogenesis via VEGFR2; upregulates growth factors; modulates NO and dopamine pathways; stabilizes gut barrier; ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect. Reported half-life: BPC-157, less than 30 min (IV and IM in rats and dogs; oral not measured); ARA-290, ~2 hrs. Routes in published studies: BPC-157, SC / IM / Oral / Intranasal; ARA-290, SC injection.

Which has stronger evidence, BPC-157 or ARA-290?

ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. BPC-157 is graded Anecdotal + Animal Studies, with 9 cited sources on its reference page and 190 indexed studies. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies.

Which is more accessible, BPC-157 or ARA-290?

Neither BPC-157 nor ARA-290 is an FDA-approved drug. Catalog status: BPC-157, Compounding Restricted; ARA-290, Investigational. FDA's Pharmacy Compounding Advisory Committee voted 8 for, 6 against, 1 abstention on 23 July 2026 to recommend BPC-157 for the 503A Bulks List; the vote is advisory and changes nothing by itself.

Are BPC-157 and ARA-290 ever combined?

BPC-157 and ARA-290 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…